Phibro Animal Health : Third Quarter - 2026 Presentation

Published: 2026-05-07 08:54:10 ET PAHC

Published on 05/07/2026 at 08:54 am EDT

Webcast and Conference Call

May 7, 2026

U.S. toll-free

+1.888.330.2022

International toll

+1.365.977.0051

Financial Results

Fiscal Year 2026

Third Quarter Ended March 31, 2026

Conference ID:

3927884

May 7, 2026

Webcast and Conference Call

Continued Sales Momentum

Q3 Total Legacy Business sales

growth of 6%

Q3 Total Consolidated sales and

adjusted EBITDA growth of 10% and 11%

Sales growth

Animal Health +13%

Mineral Nutrition +10%

Performance Products -17%

Strong Performance in Animal Health

Q3 Total Animal Health sales

and adjusted EBITDA growth of 13% and 13%

Sales growth

MFAs and other Legacy +5%

MFAs and other Z-Product

+25%

Nutritional specialties +8%

Vaccines +16%

Q3 Total Legacy Animal Health

Business sales growth of 8%

Strong continued demand for

animal protein

Business Updates

Regulatory development in

Brazil affecting certain antimicrobial products

Increased the size of our

revolving credit facility by $125 million

Launched our Sustainable

Solutions Platform, including the introduction of VERRATAIN Verified Sustainability Solutions

Updated 2026 guidance

Net sales of $1.460 billion to $1.500 billion

Adjusted EBITDA of $247 million to $255 million

Adjusted EPS of $2.98 to

$3.10

GAAP EPS $2.25 to

$2.44

FY2026 Full Year Guidance

3 May 7, 2026

Webcast and Conference Call

Third Quarter, Year-on-Year comparison

$ in millions, except per share data

YOY

FY25

FY26

%∆

Consolidated

Net Sales

$ 347.8

$ 383.5

10%

Net Income

$ 20.9

$ 24.0

15%

Diluted EPS

$ 0.51

$ 0.59

16%

Adjusted EBITDA

$ 54.9

$ 60.8

11%

Adjusted Net Income

$ 26.2

$ 31.2

19%

Adjusted Diluted EPS

$ 0.64

$ 0.76

19%

Year-On-Year % changes are in comparison to the same period of the prior fiscal year

Adjusted results adjust GAAP results for one-off items, acquisition-related items and other (income) expense, including foreign currency (gains) losses.

4 May 7, 2026

Webcast and Conference Call

Third Quarter, Year-on-Year comparison

$ in millions

Animal Health

FY25

FY26

YOY

%∆

Net Sales

$ 258.4

$ 291.2

13%

MFAs & other Legacy

104.7

109.9

MFAs & other Z-Product

77.0

95.9

25%

Total MFA & other

181.6

205.8

13%

Nutritional specialties

43.4

46.8

Vaccines

33.4

38.6

16%

Adj. EBITDA

$ 63.1

$ 71.1

13%

Adj. EBITDA Margin

24.4%

+0 bps

Year-On-Year % changes are in comparison to the same period of the prior fiscal year

Adjusted results adjust GAAP results for one-off items, acquisition-related items and other (income) expense, including foreign currency (gains) losses.

5 May 7, 2026

Webcast and Conference Call

Third Quarter, Year-on-Year comparison

YOY

FY25

FY26

%∆

$ in millions

Mineral Nutrition

Net Sales

$ 66.8

$ 73.4

10%

Adj. EBITDA

$ 5.8

$ 5.1

(11%)

Adj. EBITDA Margin

8.6%

7.0%

-160 bps

Performance Products

Net Sales

$ 22.7

$ 18.9

(17%)

Adj. EBITDA

$ 3.3

$ 2.2

(33%)

Adj. EBITDA Margin

14.7%

11.7%

-300 bps

Corporate

Adj. EBITDA

$ (17.3)

$ (17.7)

Year-On-Year % changes are in comparison to the same period of the prior fiscal year

Adjusted results adjust GAAP results for one-off items, acquisition-related items and other (income) expense, including foreign currency (gains) losses.

6 May 7, 2026

Webcast and Conference Call

March 31, 2026

Free Cash Flow (1)

Free cash flow was $13 million for the TTM -- positive cash from operating activities of $66 million, less capital expenditures of $(53) million.

Cash and cash equivalents of $77.5 million

Leverage

3.1x gross leverage ratio; $741 million total debt / $241 million TTM adjusted EBITDA

2.8x net leverage ratio; $663 million debt / $241 million TTM adjusted EBITDA

Interest Rates

Our debt is hedged with Interest Rate Swaps as follows: 1) $150 million of debt at fixed interest rate of 3.18% + margin through September 2029; and 2) $275 million of debt at fixed interest rate of 3.64% + margin through February 2030. In addition, we entered a Forward Starting Interest Rate Collar starting in July 2025 for $250 million with an interest rate cap and floor of 4.75% and 1.99%, respectively, through June 2026.

Dividend

Quarterly dividend of $0.12 per share; $4.9 million dividend paid

(1) Free cash flow equals cash flow from operating activities less capital expenditures TTM: trailing twelve months

7 May 7, 2026

Webcast and Conference Call

Fiscal Year 2026

Consolidated

Actual

FY 2025

$ in millions, except earnings per share (EPS) data

FY 2026

Low

High

FY 2026

Updated

Low

High

Net Sales

$ 1,296

Net Income

$ 48

Diluted EPS

$ 1.19

Adjusted EBITDA

$ 184

Adjusted Net Income

$ 85

Adjusted Diluted EPS

$ 2.09

Adjusted Effective Tax Rate Range

25.0%

$ 1,450

$ 1,500

$ 85

$ 95

$ 2.08

$ 2.32

$ 245

$ 255

$ 120

$ 127

$ 2.93

$ 3.10

~ 25%

$ 1,460

$ 1,500

$ 92

$ 100

$ 2.25

$ 2.44

$ 247

$ 255

$ 122

$ 127

$ 2.98

$ 3.10

~ 25%

8 May 7, 2026

Webcast and Conference Call

PAHC Company Overview

Q&A

9 May 7, 2026

Webcast and Conference Call

May 7, 2026 Webcast and Conference Call

Disclaimer

Phibro Animal Health Corporation published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2026 at 12:53 UTC.